Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that homologous PRP (h-PRP) significantly increased hair density more than both nonactivated (n-PRP) and activated (a-PRP) autologous PRP in patients with androgenetic alopecia, suggesting h-PRP as a potentially more effective treatment option for hair loss.

This study reported that a new laser scanner using 655 nm red and 808 nm infrared lasers significantly improved hair density in patients with androgenic alopecia compared to both a laser hat and no treatment, without observable adverse effects.

In this pilot study, botulinum toxin was found to be a safe and effective treatment for androgenetic alopecia in most participants, though larger studies are needed to confirm these findings.

This research observed that among young men with androgenic alopecia, there was a significant association with metabolic syndrome compared to healthy controls, suggesting AGA as a potential early marker for metabolic risk.

This study found that minoxidil suppressed androgen receptor functions and stability, suggesting its potential use in treating diseases related to the androgen-AR pathway.

This pilot study found that a multimodal minoxidil microemulsion with diclofenac and tea tree oil was more effective and safer than minoxidil alone for treating androgenic alopecia over 32 weeks.

This study found that males with androgenetic alopecia had a higher risk of coronary artery disease, with significant differences in several lipid and blood pressure markers compared to controls.

In this study, men taking 1 mg/day of finasteride for 12 months showed minor metabolic changes and slight improvements in glucose metabolism.

This study found that finasteride (1 mg/day) appeared to reverse the shortening of the hair cycle in androgen sensitive sites but did not convert miniaturized hair into terminal hair.

This review discusses female androgen insufficiency syndrome and reports no new clinical results; the authors suggest that testosterone replacement may alleviate symptoms like loss of libido and fatigue.

This article discusses the combination of mechanical hair removal and medication use for hirsutism improvement, noting that no drugs are approved for this condition in North America, and calls for well-designed comparative studies.

This study found no correlation between acne severity and clinical signs of androgenicity in women, suggesting factors other than hyperandrogenaemia may contribute to acne development.

This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.

This study found that African American men with prostate cancer have higher rates of somatic and germline androgen receptor mutations than Caucasian American men, which may contribute to ethnic differences in disease progression and outcomes.

This review discusses advancements in cell culture techniques for hair growth treatments and provides insights into the potential and challenges of follicular cell implantation, reporting no new clinical results.

In this study, oral finasteride improved the quality of life for male patients with androgenetic alopecia, but it did not significantly reduce anxiety or correlate with reported anxiety levels.

This study found significant hormonal differences, including elevated cortisol and androstenedione levels, in both male and female androgenic hair loss patients compared to controls, suggesting complex hormonal interactions in the condition.

Men with baldness have higher levels of specific proteins, suggesting local hormone production may play a role in hair loss.

This article reviews the interaction between sex hormone pathways and morphogenesis-related signaling in epithelial organ development, using a chicken model to propose testable hypotheses, but reports no new clinical results.

Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.

This study found that dihydrotestosterone induced hair loss and changes in hair morphology in male C57BL/6 mice, effects that could be partially reversed by the AR antagonist bicalutamide.

This study generated FGF5-knockout Dorper sheep using the CRISPR/Cas9 system, resulting in significantly increased fine-wool and active hair-follicle density, and explored downstream signaling pathways for potential applications in androgen alopecia treatment.

This study found that patients with androgenetic alopecia reported more impact on their quality of life in terms of emotions, functioning, and symptoms than those with alopecia areata.

This review suggests that platelet-rich plasma is a low-risk treatment for androgenic alopecia with good patient satisfaction and positive objective outcomes, but further research is needed to refine methods and standardize outcome measurements.

This review finds preliminary evidence suggesting that topical finasteride may significantly reduce hair loss and increase hair counts in treating androgenetic alopecia, with a promising safety profile.

In this study, YK11 was found to promote osteoblast cell proliferation and differentiation through activation of non-genomic signaling pathways in mouse osteoblast cells.

This study found that higher BMI in PCOS patients at a Chinese clinic was associated with functional disorders of androgen excess, suggesting BMI may predict hyperandrogenism in this population.

The study observed that testosterone reduced knee range of motion in ovariectomized female rats, potentially by downregulating specific relaxin receptor isoforms, with its effects mediated via dihydro-testosterone.

In this study, early-onset androgenetic alopecia in men was associated with a higher prevalence of metabolic syndrome and carotid atherosclerosis compared to controls, suggesting cardiovascular screening might be beneficial for this group.

In this study, no association was found between the AR gene and type II androgenetic alopecia in Egyptian women, suggesting it is not a useful biomarker for predisposition.